Berkeley Lights, Inc. (Nasdaq: BLI), a pacesetter in digital cell biology, and Curia, previously AMRI, a number one contract analysis, growth and manufacturing group (CDMO), as we speak introduced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to speed up and broaden its antibody-based drug discovery capabilities.
The Beacon system workflow at Curia leverages its proprietary Pentamice® platform, CHO-GSN℠ and TunaCHO℠ platforms, in addition to the corporate’s antibody and cell-line engineering methods. The Pentamice® platform, CHO-GSN℠ and TunaCHO℠ platforms had been developed at LakePharma, which Curia acquired in 2021. Study extra at curiaglobal.com/beacon.
With the addition of the Beacon system, Curia is ready to present a seamless and complete portfolio of state-of-the-art applied sciences and expertise for speedy development of shopper antibody packages. Its options tackle the earliest stage of discovery, via maturation and growth, to fabricate of drug substance and remaining drug merchandise below GMP.
Pace counts in drug discovery, so the flexibility to conduct high-throughput, single-cell experiments is a sport changer, enabling plentiful and various leads,” mentioned Christopher Conway, president, R&D, Curia. “Superior applied sciences such because the Berkeley Lights platform are revolutionizing antibody discovery, tackling key ache factors that confront innovators, akin to lengthy timelines and restricted variety of sequences. Our demonstrated capacity to combine applied sciences, course of and scientific experience finally allows us to speed up the time to clinic and the advance of life-changing life science.”
Curia scientists evaluated quite a lot of applied sciences and chosen the Beacon system based mostly on its confirmed capabilities and seamless integration in Curia’s end-to-end manufacturing worth chain. With its talents to ship towards a spread of targets that fail with conventional applied sciences, mixed with the confirmed immunological range inherent in its PentaMice® platform, Curia expects to ship distinctive and various antibody sequences with complete knowledge evaluation below timelines which can be weeks in period fairly than months, and growth candidates in six months or fewer.
We’re excited to accomplice with Curia, a number one CDMO, of their adoption of the Berkeley Lights platform for antibody discovery. They’ll now speed up the timeline wherein vital therapeutics could make it to the clinic,” mentioned Eric Hobbs, Ph.D., president of Antibody Therapeutics at Berkeley Lights. “Curia is exhibiting their dedication to adopting cutting-edge applied sciences that extra quickly and successfully discover the most effective cells, particularly for hard-to-identify antibodies.”
About Curia
Curia, previously AMRI, is a number one contract analysis, growth and manufacturing group offering services and products from R&D via business manufacturing to pharmaceutical and biopharmaceutical prospects. Curia’s 3,700 workers at 29 areas throughout the US, Europe and Asia assist its prospects advance from curiosity to remedy. Study extra at CuriaGlobal.com.
About Berkeley Lights
Berkeley Lights is a number one digital cell biology firm targeted on enabling and accelerating the speedy growth and commercialization of biotherapeutics and different cell-based merchandise for our prospects. The Berkeley Lights Platform captures deep phenotypic, useful and genotypic info for 1000’s of single cells in parallel and may ship the reside biology prospects need within the type of the most effective cells. Our platform is a completely built-in, end-to-end answer, comprising proprietary consumables, together with our OptoSelect™ chips and reagent kits, superior automation methods, and utility software program. We developed the Berkeley Lights Platform to offer essentially the most superior setting for speedy useful characterization of single cells at scale, the aim of which is to determine an business normal for our prospects all through their cell-based product worth chain.
Berkeley Lights’ Beacon® and Lightning™ methods and Tradition Station™ instrument are FOR RESEARCH USE ONLY. Not to be used in diagnostic procedures.
Ahead-looking statements
To the extent that statements contained on this press launch usually are not descriptions of historic info relating to Berkeley Lights or its merchandise, they’re forward-looking statements reflecting the present beliefs and expectations of administration. Such forward-looking statements contain substantial identified and unknown dangers and uncertainties that relate to future occasions, and precise outcomes and product efficiency might differ considerably from these expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to replace or revise any forward-looking statements. For an extra description of the dangers and uncertainties referring to the Firm’s progress and continuous evolution see the statements within the “Danger Elements” sections, and elsewhere, in our filings with the US Securities and Alternate Fee.
